Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, highlights findings from chronic lymphocytic leukemia (CLL) studies presented at the 2021 American Society of Hematology (ASH) Annual ...
Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor. Changes to the ...
The approvals of obinutuzumab, ibrutinib, and idelalisib provide clinicians with new treatment optio Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results